Brief: Phase 1 Clinical Trial Data Indicate Igc’S Thc-Based Investigational New Drug May Reduce Symptoms Of Dementia In Alzheimer’S Patients
02/12/2021 14:39
Dec 2 (Reuters) - India Globalization Capital Inc IGC.A :
* PHASE 1 CLINICAL TRIAL DATA INDICATE IGC’S THC-BASED
INVESTIGATIONAL NEW DRUG MAY REDUCE SYMPTOMS OF DEMENTIA IN
ALZHEIMER’S PATIENTS
Source text for Eikon: ID:nBw9Mkb1Ya
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment